

Markus Hinder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8279299/publications.pdf>

Version: 2024-02-01

33
papers

913
citations

567281

15
h-index

477307

29
g-index

36
all docs

36
docs citations

36
times ranked

1027
citing authors

#	ARTICLE	IF	CITATIONS
1	Changing R&D models in research-based pharmaceutical companies. <i>Journal of Translational Medicine</i> , 2016, 14, 105.	4.4	231
2	Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension. <i>Hypertension</i> , 2017, 69, 32-41.	2.7	98
3	The effect of LCZ696 (sacubitril/valsartan) on amyloid β concentrations in cerebrospinal fluid in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 878-890.	2.4	89
4	Translational precision medicine: an industry perspective. <i>Journal of Translational Medicine</i> , 2021, 19, 245.	4.4	51
5	Role of Renal Nerves in the Stimulation of the Renin System by Reduced Renal Arterial Pressure. <i>Hypertension</i> , 1999, 34, 1101-1105.	2.7	38
6	T-type and L-type calcium channel blockers exert opposite effects on renin secretion and renin gene expression in conscious rats. <i>British Journal of Pharmacology</i> , 1998, 124, 579-585.	5.4	36
7	Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?. <i>Journal of Translational Medicine</i> , 2018, 16, 119.	4.4	36
8	The upside of being a digital pharma player. <i>Drug Discovery Today</i> , 2020, 25, 1569-1574.	6.4	33
9	Pharmacokinetics of Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Male Subjects: Pharmacokinetic Model Development for Phase 2/3 Simulation of Exposure. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 37-44.	2.0	29
10	LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e57-e70.	3.6	29
11	Licoglitflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2595-2599.	4.4	27
12	R&D efficiency of leading pharmaceutical companies – A 20-year analysis. <i>Drug Discovery Today</i> , 2021, 26, 1784-1789.	6.4	25
13	Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 691-702.	4.7	24
14	Use of Population Pharmacokinetic Modeling and Monte Carlo Simulation To Describe the Pharmacodynamic Profile of Cefditoren in Plasma and Epithelial Lining Fluid. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1945-1951.	3.2	23
15	Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 109-116.	1.6	19
16	Effect of Steady-State Enoxacin on Single-Dose Pharmacokinetics of Roflumilast and Roflumilast N-Oxide. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 586-593.	2.0	17
17	Open innovation: A paradigm shift in pharma R&D?. <i>Drug Discovery Today</i> , 2022, 27, 2395-2405.	6.4	17
18	Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, and acetylsalicylic acid. <i>Thrombosis and Haemostasis</i> , 2006, 95, 224-228.	3.4	10

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetic/Pharmacodynamic Relationships for Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 45-51.	2.0	9
20	The Art of Virtualizing Pharma R&D. <i>Drug Discovery Today</i> , 2019, 24, 2105-2107.	6.4	8
21	Big Techs and startups in pharmaceutical R&D – A 2020 perspective on artificial intelligence. <i>Drug Discovery Today</i> , 2021, 26, 2226-2231.	6.4	8
22	Systematic risk identification and assessment using a new risk map in pharmaceutical R&D. <i>Drug Discovery Today</i> , 2021, 26, 2786-2793.	6.4	8
23	Comparison of the efficacy and safety of losartan (50–100 mg) with the T-type calcium channel blocker mibefradil (50–100 mg) in mild to moderate hypertension. <i>Fundamental and Clinical Pharmacology</i> , 2000, 14, 31-41.	1.9	7
24	Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteers. <i>Thrombosis and Haemostasis</i> , 2005, 93, 794-795.	3.4	7
25	Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 802-814.	4.7	6
26	The present and future of project management in pharmaceutical R&D. <i>Drug Discovery Today</i> , 2021, 26, 1-4.	6.4	5
27	A framework to guide dose & regimen strategy for clinical drug development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1276-1280.	2.5	5
28	Investigation and Management of Stool Frequency and Consistency Associated With SGLT1 Inhibition by Reducing Dietary Carbohydrate: A Randomized Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 995-1002.	4.7	3
29	Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial. <i>Cardiovascular Research</i> , 2021, 117, 320-329.	3.8	3
30	Evaluation of cardiac parameters and other safety outcomes of brolicizumab treatment in patients with neovascular age-related macular degeneration. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00897.	2.4	2
31	Comparison of the Initial Hemodynamic Effects of Immediate-Release versus Sustained-Release Isosorbide-5-Mononitrate following Single Oral Doses. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 168-176.	2.0	1
32	Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1121-1130.	1.9	1
33	Introduction to the Book. , 2016, , 1-9.		0